Lates News

AstraZeneca announced last week that it will invest $5 billion to strengthen its research and manufacturing capabilities in the United States, becoming the latest multinational pharmaceutical company to respond to the Trump administration's call for "reshoring" manufacturing. The company's CEO, Soriot, revealed on Tuesday that he has discussed industry development plans with the Trump administration, stating, "This investment demonstrates our confidence in the growth of the U.S. market. The leader in biopharmaceutical innovation today is undoubtedly the United States." He also criticized the lack of research and development vitality in Europe.